

available at www.sciencedirect.comjournal homepage: www.ejconline.com

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation [☆]

Maja J.A. de Jonge ^{a,c,*}, Marije Slingerland ^{b,c}, Walter J. Loos ^a, Erik A.C. Wiemer ^a, Herman Burger ^a, Ron H.J. Mathijssen ^a, Judith R. Kroep ^b, Margret A.G. den Hollander ^b, Diane van der Biessen ^a, Mei-Ho Lam ^a, Jaap Verweij ^a, Hans Gelderblom ^b

^a Erasmus University Medical Center Daniel Den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands

^b Leiden University Medical Center, Department of Clinical Oncology, Leiden, The Netherlands

ARTICLE INFO

Article history:

Received 31 May 2010

Accepted 14 July 2010

Available online 26 August 2010

Keywords:

LiPlaCis

Liposomal

Cisplatin

Phase I

Solid tumour

ABSTRACT

Purpose: To evaluate the safety and tolerability of LiPlaCis, a liposomal formulated platinum compound, in patients with solid tumours and to determine the maximum tolerated dose (MTD) of intravenous (i.v.) LiPlaCis. and to assess plasma and urine pharmacokinetics and plasma biomarkers.

Patients and methods: Patients with solid tumours without standard therapeutic options were enrolled to receive LiPlaCis administered as a 1 h infusion without additional hydration every 3 weeks until RECIST progression or unacceptable toxicity. Cohorts of 3–6 patients were treated at each dose level until MTD was reached.

Results: Eighteen patients were enrolled and 64 cycles were delivered. At the first dose level 3 patients experienced an infusion reaction. Despite prophylactic pre-medication and prolongation of the infusion to 2 h in further patients, three other patients had mild acute infusion reactions. Toxicity at the fifth dose level of 120 mg consisted of grade 2 renal toxicity reversible after hydration in 2 patients and grade 4 thrombocytopenia in one of these patients. Peak plasma concentrations and AUC were dose proportional. The interpatient variability in the clearance of total LiPlaCis-derived platinum was 41%. Platinum was excreted via the urine mainly during the first 24 h after administration. Investigated plasma biomarkers sPLA₂ and SC5b-9 were related to, but not predictive for, acute infusion reactions.

Conclusion: The observed safety profile suggests no benefit over standard cisplatin formulations and LiPlaCis will require reformulation to enable further development.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

Cisplatin-based anticancer therapies are widely used in the treatment of solid tumours. Dose-limiting toxicities include renal-tubular dysfunction, peripheral-neuropathy and oto-

toxicity, the first of which is due to rapid renal clearance of cisplatin and can be largely prevented by extensive pre- and post-hydration surrounding cisplatin administration.^{1–3}

Widening cisplatin's therapeutic window by making the drug more tumour-selective seems attractive. Liposomal drug

[☆] This clinical trial was registered as EUDRACT 2006-006637-40.

* Corresponding author: Tel.: +31 10 439 1760; fax: +31 10 439 1003.

E-mail address: m.dejonge@erasmusmc.nl (M.J.A. de Jonge).

^c Authors contributed equally.

0959-8049/\$ - see front matter © 2010 Elsevier Ltd. All rights reserved.

doi:10.1016/j.ejca.2010.07.015

delivery could serve this purpose, but was previously limited by the fast clearance from the blood. Addition of polyethylene glycol to the surface of liposomes resolved this problem and leads to preferential trapping and accumulation of liposomes in the leaky tumour vasculature resulting in enhanced drug exposure at the tumour site.⁴

However, in particular true for hydrophilic drugs like cisplatin, which cannot readily pass the liposomal lipid membrane, liposomal degradation and subsequent drug release into the tumour is an essential prerequisite for effect. The absence of drug release from the liposomes and the resulting absence of DNA-adduct formation, explained the lack of activity of SPI-077, a liposomal cisplatin formulation.^{5,6}

LiPlaCis is a novel liposomal formulation of cisplatin. The LiPlaCis liposomes (i.e. LiPlasomes) are designed to be degraded by secretory phospholipase A₂ (PLA₂), a relatively tumour selective enzyme and thereby release the encapsulated cisplatin.^{7,8} The use of enzymes, such as PLA₂, for triggered-drug release provides a novel tumour selective drug delivery approach. Pre-clinical proof of principle has been demonstrated *in vitro* and *in vivo*.^{9,10}

The aim of this study was to define the maximum tolerated dose (MTD), the recommended phase II dose, pharmacokinetics and pharmacodynamics, as well as the preliminarily anti-tumour effects of a three-weekly schedule of LiPlaCis in patients with solid tumours.

2. Patients and methods

2.1. Drug formulation

This study was an open-label, dose-escalating phase I study of LiPlaCis in patients with advanced solid tumours. LiPlaCis was supplied by LiPlasome Pharma A/S as a concentrate for infusion in vials containing 2 mL (1 mg/mL) each as a white opalescent dispersion. The product must be stored at $T = -80^{\circ}\text{C}$ in order to ensure stabilisation of the liposomes. The liposomes of LiPlaCis are composed of 1,2-distearoyl-*sn*-glycero-3-phosphocholine, 1,2-distearoyl-*sn*-glycero-3-[phosphor-*rac*-(1-glycerol)] (sodium salt) and 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine-*N*-[methoxy(polyethylene glycol)-2000] (ammonium salt). In addition, sodium chloride, sucrose and disodium hydrogen phosphate are added to stabilize the liposomes. After thawing in a water bath at room temperature the content of the vials was added to a polyvinylchloride bag with saline to a total volume of 500 mL. The solution was kept at room temperature protected from light until administration which had to take place within 8 h after preparation.

2.2. Study design

LiPlaCis was administered intravenously in 1 h once every 3 weeks as long as there was no evidence of progressive disease (PD) or unacceptable toxicity. Escalation followed in a 3 + 3 design with increase of 20–100% from the previous dose level based on toxicity and pharmacokinetics. The MTD was defined as the dose with two or more patients with dose-limiting toxicity (DLT) in a cohort of 3 or 6 patients. Toxicity was evaluated using the CTC version 3.0.¹¹ DLT was defined as CTC grade 4 neutropaenia, grade 4 thrombocytopenia, or grade 3

thrombocytopenia complicated with bleeding, persistent grade 2 neurotoxicity, persistent serum creatinine $\geq 2 \times$ upper limit of normal (ULN), drug-related non-haematological grade 3–4 toxicity or a delay in re-treatment with LiPlaCis of more than 2 weeks. The recommended dose for phase II (RD) was defined as the immediate-dose level below MTD.

If 2 patients at any dose level experienced an infusion reaction of at least grade 2, reduction in infusion rate and pre-medication would be introduced. No prophylactic antiemetics were administered. Once 2 patients experienced nausea or vomiting grade 2 or more, prophylactic use of antiemetics would be introduced for both the patients in question and the remaining patients. Hydration was not used routinely, however if nephrotoxicity was observed in a patient, both pre- and post-hydration would be introduced for the remaining cycles of this patient. In case of nephrotoxicity in multiple patients, a routine pre- and post-hydration schedule was to be implemented. Patients with measurable disease were assessed for anti-tumour activity by RECIST every 3 cycles and patients without measurable disease were assessed clinically.¹² Each subject, receiving at least 1 cycle was assigned a best response. The analysis of safety was based on the subjects who received at least one dose of LiPlaCis.

2.3. Eligibility criteria

Eligibility included a histological- or cytological- documented locally advanced or metastatic solid tumour refractory to standard therapy or for which no effective therapy existed and ECOG performance status 0–2. Required laboratory values included: absolute neutrophil count $\geq 1.5 \times 10^9/\text{L}$, platelet count $\geq 100 \times 10^9/\text{L}$, haemoglobin $\geq 9 \text{ g/dL}$, total bilirubin $\leq 1.5 \times \text{ULN}$, alkaline phosphatase $\leq 2.5 \times \text{ULN}$, creatinine and blood urea within normal limits, unless creatinine clearance was $\geq 60 \text{ mL/min}$ calculated according to Cockcroft–Gault formula, aspartate aminotransferase and alanine aminotransferase $\leq 2.5 \times \text{ULN}$, or $\leq 5 \times \text{ULN}$ in case of liver metastases. The study was approved by the institutional ethical committee and patients gave written informed consent prior to treatment.

2.4. Pharmacokinetics and pharmacodynamics

Serial blood samples for plasma total LiPlaCis-derived platinum (i.e. cisplatin-derived liposomal- associated plus non-liposomal associated platinum) concentration measurements as well as for secretory phospholipase A₂ (sPLA₂) and the complement activation marker SC5b-9 were collected over a 5-d period following the start of the infusion in cycle 1. Blood-samples were collected in standard blood collection lithium- heparin tubes prior to LiPlaCis infusion, halfway the infusion, 5 min before the end of infusion and 30 min, 1, 3, 6, 8, 24, 47, 71 and 95 h after the end of infusion. In case the infusion was stopped due to an acute infusion reaction, additional blood samples were collected at the point of interruption and restart of the infusion. Samples were centrifuged within 10 min after collection at 2800–3000g for 10 min at 4 °C. The plasma supernatant was stored at $T < -70^{\circ}\text{C}$ upon analysis.

Urine samples for the analysis of LiPlaCis-derived platinum concentrations were collected as voided in standard

polypropylene containers prior to start of the infusion and during the following period after start of infusion: 0–6, 6–12, 12–24, 24–48, 48–72 and 72–96 h. The total volume was recorded and 3-mL aliquot of each portion stored at $T < -70^{\circ}\text{C}$ upon analysis.

Total LiPlaCis-derived platinum was determined by a validated, atomic absorption spectrophotometer method for cisplatin-derived platinum, with a lower limit of quantitation established at $0.200\text{ }\mu\text{g/mL}$, essentially reported previously.¹³ Pharmacokinetic parameter estimates of platinum were derived from weighted (1/y) two-compartmental model analysis using WinNonlin version 5.2.1 (Pharsight Corp., Mountain View, CA; model 10). Urine concentrations of total LiPlaCis-derived platinum were determined likewise. The lower limit of quantitation was validated at $1.00\text{ }\mu\text{g/mL}$ platinum in urine.

Plasma concentrations of sPLA₂ were determined by an enzyme immunoassay (EIA) based on the double-antibody 'sandwich' technique specific for type IIa sPLA₂ (sPLA₂ human Type IIA EIA Kit, Cayman, Ann Arbor, Michigan, United States of America (USA)). Plasma samples were also analysed for SC5b-9, the terminal complement complex (TCC, SC5b-9) generated by the assembly of C5 through C9 as a consequence of activation of the complement system, using a SC5b-9 Plus EIA Kit (Quidel, San Diego CA, USA). ELISA measurements were performed according to the manufacturer's protocols.

2.5. Statistical analysis

Statistical analysis was performed using SPSS version 15.0. Potential differences in PK parameters between subgroups of patients were evaluated with ANOVA and T-test, whilst correlations were tested with linear regression analysis.

3. Results

3.1. Patients, doses and toxicity

From May 2008 to November 2009 18 patients were enrolled into this study. Baseline patient demographics and disease characteristics are outlined in Table 1.

Overall, a total of 64 cycles of LiPlaCis were administered with a median of 3 cycles per patient (range 1–15). Three patients were treated at the first dose level of 10 mg with one-infusion reaction grade 2. Therefore three additional patients were enrolled at dose level 1. In one of them a grade-2 infusion reaction occurred within a few minutes of starting the first infusion, but without significant systemic reactions. After administration of clemastine and dexamethason, the patients received the remainder of the infusion successfully. Due to the fact that 2 patients experienced a \geq grade-2 reaction requiring treatment, reduction of infusion rate to 50% and routine pre-medication with a combination of clemastine 2 mg intravenous (i.v.) and dexamethason 10 mg i.v., were introduced. Three patients were treated at dose levels 2–5 (20, 40, 80 and 120 mg), without first cycle DLTs. At each dose level 2, 4 and 5, 1 patient had a grade-2 infusion reaction. The patient at dose level 4 experienced a recurrent-infusion reaction (grade 3) in the second cycle despite additional pre-medication and was taken off study. Grade 1–2 nephrotoxicity, reversible after hydration, was observed in 1 patient at the

Table 1 – Baseline demographics and patient characteristics.

Baseline characteristics	Patients (n (%))
<i>Gender</i>	
Male	10 (55)
Female	8 (45)
<i>Age (years)</i>	
Median (range)	58 (39–75)
<i>ECOG performance status</i>	
0	4 (22)
1	14 (78)
<i>Tumour type</i>	
Breast	2 (11)
Melanoma	2 (11)
Oesophagus	2 (11)
Prostate	2 (11)
Parotid carcinoma	2 (11)
Oro-/hypopharyngeal cancer	2 (11)
Urothelial carcinoma	2 (11)
Other ^a	4 (22)

^a Adenoid cystic carcinoma, cancer of unknown primary, non-small-cell lung cancer, sarcoma.

second dose level and 2 patients at the fifth dose level. At dose level 5, 1 patient had a DLT in the second cycle consisting of grade 4 thrombocytopaenia, grade 2 renal toxicity and schistocytes based on haemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) (Table 2). A second patient treated at this dose also developed a grade 2 renal toxicity in the first treatment cycle.

Given the frequent infusion reactions and the high incidence of renal toxicity implicating no apparent practical benefit over standard formulated cisplatin it was concluded that without reformulation further development was precluded.

Response per RECIST was assessed in 12 patients, because 6 patients stopped treatment before their first planned disease evaluation after cycle 3 (2 patients on their own request, 2 because of recurrent infusion reactions and 2 because of DLT). Three from the 12 evaluable patients had stable disease (SD) at 9 weeks whereas the remaining 9 patients showed PD.

3.2. Pharmacokinetics

All 18 patients were evaluable for plasma-pharmacokinetic analysis. The observed plasma concentration, time data could be best fitted by a two-compartmental model in 17 patients, whilst a one-compartmental model best fitted the data of 1 patient treated at the first dose-level of 10 mg, for which platinum could be quantitated only up to 8 h after end of infusion (i.e. platinum concentrations below $0.200\text{ }\mu\text{g/mL}$). A summary of the pharmacokinetic parameters is presented in Table 3. Peak plasma concentrations were observed at or shortly after the end of infusion, irrespective of infuse duration. Peak plasma concentrations and AUC were dose-proportional. The interpatient variability in the clearance of total LiPlaCis-derived platinum was 41% and increased to 46% after correction for patient's individual body surface area. In addition, clearance was independent of gender ($P = 0.95$; T-test) and dose ($P = 0.59$; ANOVA) and was not related to age ($P = 0.94$; linear

Table 2 – Number of patients with treatment-related adverse events in all cycles.

Adverse event	Grade	10 mg (n = 6)		20 mg (n = 3)		40 mg (n = 3)		80 mg (n = 3)		120 mg (n = 3)	
		1–2	3–4	1–2	3–4	1–2	3–4	1–2	3–4	1–2	3–4
Leucopenia	1			1		1		1		–	
Neutropenia	–			–		–		–		–	
Thrombocytopenia	2			–		–		–		–	1
Anaemia	3			3		1		2		2	
Nausea	3			2		1		2		2	
Vomiting	2			–		–		–		1	
Diarrhoea	–			1		–		–		–	
Mucositis	–			–		–		1		–	
Nephrotoxicity	1			3		–		–		2	
Neurotoxicity	2			2		1		1		2	
Fatigue	4			3		2		1		2	
AST/ALT	4			1		1		1		2	
Infusion reaction	3			1		–		1 ^a	1 ^a	1	

^a Same patient.**Table 3 – Mean \pm SD plasma pharmacokinetics^a of total LiPlaCis-derived platinum during course 1.**

Dose (mg)	Number of patients	C_{\max}^b ($\mu\text{g/mL}$)	$T_{1/2\alpha}$ (h)	$T_{1/2\beta}$ (h)	AUC ($\mu\text{g h/mL}$)	CL (mL/h)	Vss (L)
10	6	1.62 ± 0.46	3.26 ± 0.56^c	80 ± 21^c	93.1 ± 31.8^c	77.5 ± 29.6^c	7.85 ± 0.81^c
20	3	2.95 ± 0.32	3.44 ± 0.35	113 ± 46	258 ± 110	56.2 ± 21.1	7.91 ± 0.12
40	3	5.50 ± 1.18	5.50 ± 1.36	141 ± 59	559 ± 259	52.9 ± 20.7	9.21 ± 0.46
80	3	11.3 ± 0.23	3.98 ± 0.42	116 ± 35	888 ± 248	61.9 ± 18.5	9.31 ± 1.15
120	3	18.8 ± 7.50	5.04 ± 1.81	132 ± 90	2711 ± 2643	49.9 ± 34.1	6.43 ± 1.73
All	18	–	4.13 ± 1.26^d	112 ± 51^d	–	61.8 ± 25.3^d	8.11 ± 1.34^d

^a Two-compartmental, except for 1 patient in 10 mg cohort which could be best fitted to a one-compartmental model.^b Visually observed, in most cases (12 of 18) 0.5 or 1 h after end of infusion.^c n = 5 (excluding patient fitted to one-compartmental model).^d n = 17 (excluding patient fitted to one-compartmental model).

regression analysis). In Fig. 1, the average total platinum concentration corrected for dose versus time curve is presented.

Platinum was below the lower limit of quantitation in most urine samples, especially at the lower dose-levels and after 24 h. Urinary excretion, however, seemed independent of the dose and if quantifiable, during the first 24 h after administration on average approximately 20% of the dose was excreted via the urine.

3.3. Pharmacodynamics

sPLA₂ levels could be analysed in 17 patients and SC5b-9 levels in 14 patients. Plasma levels of sPLA₂ and SC5b-9 were readily detected in both baseline (pre-treatment) samples as well as on-therapy samples. Although the absolute sPLA₂ baseline plasma concentrations showed a high variability ranging from 1.5 to 13.7 ng/mL with a median of 6.3 ng/mL, relative sPLA₂ plasma levels were not affected upon administration of the liposomal- encapsulated cisplatin (LiPlaCis). The spectrum of SC5b-9 baseline levels displayed an even higher variation (range: 18–723 ng/mL; median: 233 ng/mL). All patients with a clinically-manifested acute infusion reaction showed an immediate increase in SC5b-9 levels after start of treatment that returned to (pre-treatment) baseline within 24 h (Fig. 2). However, the baseline sPLA₂ plasma levels




Fig. 1 – Average dose normalized concentration–time curve of LiPlaCis-derived platinum in plasma fitted to a two compartmental model. The patients with the relative fast clearance (fitted to a one-compartmental model), treated at the first dose-level of 10 mg and the patient with the relative slow clearance, treated at the dose-level of 120 mg, are presented with the closed symbols.

in the patients with an acute infusion reaction (n = 5) did not differ from those observed in the other 12 patients




Fig. 2 – Plasma levels of the terminal complement complex (SC5b-9) in a typical representative patient with LiPlaCis infusion reaction. SC5b-9 concentrations were determined by ELISA in plasma samples before infusion with LiPlaCis ($t = 0$), halfway during the infusion ($t = 60$ min), 5 min before the end of infusion ($t = 115$ min) and at regular time points (30 min, 1, 3, 6, 8, 24, 47, 71 and 95 h) after end of infusion. Evidently, a clear increase in SC5b-9 levels was noted during and directly after LiPlaCis administration, indicative of the acute infusion reaction of this patient to LiPlaCis.

(mean \pm SD: 5.9 ± 1.5 ng/mL versus 7.5 ± 4.3 ng/mL; $P = 0.42$; T-test). Furthermore, no correlation was found between the baseline sPLA₂ levels and the plasma PK parameter $T_{1/2\alpha}$ (Pearson's coefficient correlation: $r = 0.044$; $P = 0.87$), indicating secretory PLA₂ levels are not associated with the plasma half life of the LiPlasomes.

4. Discussion

This study was designed to evaluate the tolerability, pharmacokinetics and pharmacodynamics of LiPlaCis, a novel liposomal formulation of cisplatin. LiPlaCis has a different toxicity profile compared to cisplatin; it seems to be less emetogenic at the dose levels studied. However, many patients experienced an acute infusion reaction related to the liposomal formulation requiring pre-medication with corticosteroids, which provides a disadvantage. Even more importantly, just like cisplatin, LiPlaCis induced renal toxicity and did not have the desired kidney-sparing effect. The severity seemed to increase with the dose administered. Already at the dose level of 20 mg, grade 1 nephrotoxicity was observed in 3 patients 2 of which had confounding factors (pneumonia and nausea). The third patient had preexisting grade 1 renal impairment. At the subsequent dose levels another 2 patients developed grade 1–2 renal toxicity. At the 120 mg dose level 2 patients developed grade 2 nephrotoxicity. In 1 patient this was due to HUS-TTP, which has been ascribed in the past to cisplatin-based chemotherapy, but is a rare side-effect.¹⁴

Lipoplatin, another liposomal-cisplatin formulation recently entered phase-III studies. During the phase-I study renal toxicity was not observed. The main toxicities of Lipoplatin constituted neutropenia, anaemia and nausea and vomiting, all limited to grade 1–2.¹⁵ In a subsequent phase Ib study combining Lipoplatin with 5-fluorouracil and

radiotherapy 18% (2/11) of the patients developed grade 1 renal toxicity to which dehydration caused by gastrointestinal discomfort might have contributed.¹⁶ This still contrasts the 33% (6/18) of the patients in our present study with LiPlaCis who developed renal toxicity.

Another major drawback of LiPlaCis was the frequent observation of non-dose related grade 2 infusion reactions despite pre-medication. Also after administration of Lipoplatin infusion reactions were observed albeit at an incidence of only 8.3%.¹⁶ For pegylated-liposomal formulation of doxorubicin the percentage of acute infusion reaction is up to 9%.¹⁷ This reaction that is typical for liposomal formulations, occurred at a rather (too) high incidence (7/18 patients, 39%) in our study. The infusion reactions were accompanied with complement activations, illustrated by an immediate increase in plasma SC5b-9 level (Fig. 2).

Pharmacokinetic profiles of total LiPlaCis-derived platinum could be best fitted to a two-compartmental model. The initial half-life ($T_{1/2\alpha}$) most likely reflects the half-life of the intact circulating liposome, whilst the secondary half-life ($T_{1/2\beta}$) is considered to primarily reflect the half-life of extra-liposomal plasma-protein bound platinum. Although the LiPlasomes were constructed to be specifically degraded by sPLA₂ and plasma sPLA₂ concentrations were highly variable between patients, no correlation between the baseline levels of sPLA₂ and the initial half-life of LiPlaCis-derived platinum was observed. Potentially, other factors contributed to the degradation of the LiPlasomes. Total plasma-platinum clearance following LiPlaCis was slower compared to total-platinum clearance following the administration of free cisplatin and Lipoplatin, however was slightly faster compared to SPI-077 derived platinum.^{15,18,19} Urinary excretion was slightly lower compared to free cisplatin and half of the excretion as observed after the administration of Lipoplatin.^{15,20}

Although the toxicity pattern of LiPlaCis differed from cisplatin toxicity, renal damage was not prevented by the formulation. Acute infusion reactions required addition of extensive pre-medication, that in turn could not completely prevent a high incidence of acute infusion reactions. Reformulation of LiPlaCis seems to be warranted prior to further development.

Conflict of interest statement

None declared.

Acknowledgement

The study was financially supported by LiPlasome Pharma A/S.

REFERENCES

- de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic

- factors for toxicity in 400 patients. *Br J Cancer* 2003;**88**(8):1199–206.
2. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. *J Clin Oncol* 1999;**17**(1):409–22.
 3. Planting AS, van der Burg ME, de Boer-Dennert M, Stoter G, Verweij J. Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. *Br J Cancer* 1993;**68**(4):789–92.
 4. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. *Oncologist* 2008;**13**(3):248–60.
 5. White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. *Br J Cancer* 2006;**95**(7):822–8.
 6. Zamboni WC, Gervais AC, Egorin MJ, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. *Cancer Chemother Pharmacol* 2004;**53**(4):329–36.
 7. Laye JP, Gill JH. Phospholipase A2 expression in tumours: a target for therapeutic intervention? *Drug Discov Today* 2003;**8**(15):710–6.
 8. Abe T, Sakamoto K, Kamohara H, et al. Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. *Int J Cancer* 1997;**74**(3):245–50.
 9. Andresen TL, Jensen SS, Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. *Prog Lipid Res* 2005;**44**(1):68–97.
 10. Jensen SS, Andresen TL, Davidsen J, et al. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. *Mol Cancer Ther* 2004;**3**(11):1451–8.
 11. <http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae3.pdf>.
 12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment of solid tumours. *J Natl Cancer Inst* 2000;**92**:205–16.
 13. de Jonge MJ, Loos WJ, Gelderblom H, et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. *J Clin Oncol* 2000;**18**(10):2104–15.
 14. Kwaan HC, Gordon LI. Thrombotic microangiopathy in the cancer patient. *Acta Haematol* 2001;**106**(1–2):52–6.
 15. Stathopoulos GP, Boulikas T, Vougiouka M, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. *Oncol Rep* 2005;**13**(4):589–95.
 16. Koukourakis MI, Giatromanolaki A, Pitiakoudis M, et al. Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. *Int J Radiat Oncol Biol Phys* 2010 [Epub ahead of print].
 17. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. *Drugs* 1997;**54**(Suppl. 4):30–45.
 18. Urien S, Brain E, Bugat R, et al. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. *Cancer Chemother Pharmacol* 2005;**55**(1):55–60.
 19. Meerum Terwogt JM, Groenewegen G, Pluim D, et al. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. *Cancer Chemother Pharmacol* 2002;**49**(3):201–10.
 20. Reece PA, Stafford I, Russell J, Gill PG. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. *J Clin Oncol* 1986;**4**(9):1392–8.